

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.
上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF PATIENT ENROLLMENT
FOR THE CLINICAL TRIAL OF IBERIS® 2ND

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on January 26, 2022, the Company completed the patient enrollment process for the clinical trial of Iberis® 2nd, the second-generation renal denervation (RDN) system product independently developed by the Company. RDN is one of the few device therapies with proven clinical efficacy to treat uncontrolled hypertension and resistant hypertension and is considered by many industry experts as having the potential to transform the treatment paradigm of hypertension. According to Frost and Sullivan (Beijing) Inc., Shanghai Branch Co. (“**Frost & Sullivan**”), Iberis® 2nd is expected to be the first approved multi-electrode RDN product in China. As compared with single-electrode RDN product candidates, our multi-electrode Iberis® 2nd can effectively reduce the duration of the procedure and radiation exposure of patients and physicians. In addition, Iberis® 2nd is the only multi-electrode RDN product candidate in China that enables combined ablation of the main renal artery and its branches. We believe that, as compared with product candidates that can only ablate the main renal artery, Iberis® 2nd is able to improve the blood pressure lowering efficacy of the RDN procedure, which Frost & Sullivan concurs. Iberis® 2nd was recognized as an “innovative medical device” by the National Medical Products Administration in November 2016 and is therefore eligible for an expedited approval process.

Looking ahead, the Company will carry on its ongoing clinical programs and bring Iberis® 2nd to the market partnering with Terumo Corporation. The Company will continue to strengthen its in-house research and development capabilities and bring innovation to clinical care.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Iberis® 2nd will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the People's Republic of China, January 26, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.